Riyadh – Mubasher: Middle East Pharmaceutical Industries Company (Avalon Pharma) entered into a strategic commercialization agreement with Bio-Thera Solutions to register Pembrolizumab in Saudi Arabia and MENA markets
Under the agreement, Bio-Thera will maintain responsibility for the development, manufacturing, and supply of BAT3306, according to a press release.
Avalon Pharma will be responsible for seeking regulatory approvals as well as commercialization in the licensed territories in Saudi Arabia and MENA.
The partnership will start reflecting on the company’s financials from 2030 onwards, estimating the incremental revenue of no less than SAR 500 million during the contract period.
Mohamed Maher Al Ghannam, Managing Director and CEO of Avalon Pharma, commented: “Partnering with Bio-Thera strengthens our ability to deliver complex biologic therapies and reflects our evolution toward a specialty-focused pharmaceutical platform.”
He indicated: “Together, we aim to improve access to high-quality oncology treatments while supporting sustainable healthcare systems across the region.”
Bert Thomas, Senior Vice President of Business Development, mentioned: “Bio-Thera is committed to expanding patient access to critical oncology therapies in Saudi Arabia and the wider MENA region. This is the first of many immuno-oncology biosimilars that Bio-Thera is developing for oncology patients in MENA and around the world.”
